The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.
Peter Michael Ellis
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Geoffrey Liu
No relevant relationships to disclose
Michael Millward
No relevant relationships to disclose
Francesco Perrone
Honoraria - Pfizer
Frances A. Shepherd
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Sophie Sun
No relevant relationships to disclose
Byoung Chul Cho
No relevant relationships to disclose
Alessandro Morabito
Consultant or Advisory Role - Pfizer
Martin R. Stockler
No relevant relationships to disclose
Rafal Wierzbicki
No relevant relationships to disclose
Victor Cohen
Consultant or Advisory Role - Pfizer
Normand Blais
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Randeep S. Sangha
Honoraria - Pfizer
Adolfo G. Favaretto
No relevant relationships to disclose
Jin Hyoung Kang
No relevant relationships to disclose
Carolyn F. Wilson
No relevant relationships to disclose
Joseph O'Connell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Keyue Ding
No relevant relationships to disclose
Glenwood D. Goss
Honoraria - Pfizer
Penelope Ann Bradbury
Research Funding - Pfizer